Compare · EW vs MYO
EW vs MYO
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and Myomo Inc. (MYO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EW and MYO operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $48.42B, about 1397.2x MYO ($34.7M).
- Over the past year, EW is up 11.7% and MYO is down 81.2% - EW leads by 92.9 points.
- MYO has been more active in the news (11 items in the past 4 weeks vs 6 for EW).
- EW has more recent analyst coverage (25 ratings vs 3 for MYO).
- Company
- Edwards Lifesciences Corporation
- Myomo Inc.
- Price
- $83.99+0.54%
- $0.89+2.96%
- Market cap
- $48.42B
- $34.7M
- 1M return
- +3.30%
- +32.92%
- 1Y return
- +11.71%
- -81.22%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- AMEX
- IPO
- 2017
- News (4w)
- 6
- 11
- Recent ratings
- 25
- 3
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Myomo Inc.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to restore function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Latest EW
- Edwards Lifesciences to Present at the BofA Securities 2026 Health Care Conference
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports First Quarter Results
- Edwards Lifesciences to Host Earnings Conference Call on April 23, 2026
- SEC Form 4 filed by Ullem Scott B.
- SEC Form 4 filed by Lippis Daniel J.
- SEC Form 4 filed by Bobo Donald E Jr
- Edwards Lifesciences upgraded by Wolfe Research with a new price target
- Two Year Data on Edwards Lifesciences' EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits
- Amendment: SEC Form SCHEDULE 13G/A filed by Edwards Lifesciences Corporation
Latest MYO
- Myomo to Report First Quarter 2026 Financial Results on May 7
- Amendment: SEC Form 10-K/A filed by Myomo Inc.
- Myomo Introduces Myomo Mobile App to Enhance Clinical Workflow and Patient Engagement
- SEC Form 4 filed by Febbo William J
- SEC Form 3 filed by new insider Febbo William J
- Myomo Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Myomo Appoints William J Febbo to its Board of Directors
- Amendment: SEC Form 4 filed by Gudonis Paul R
- SEC Form 4 filed by Henry David A
- SEC Form 4 filed by Gudonis Paul R